|Numéro de publication||US20070005083 A1|
|Type de publication||Demande|
|Numéro de demande||US 11/515,181|
|Date de publication||4 janv. 2007|
|Date de dépôt||1 sept. 2006|
|Date de priorité||30 avr. 1997|
|Autre référence de publication||EP1157663A1, US7670373, US8136520, US20100114157, WO1998048706A1|
|Numéro de publication||11515181, 515181, US 2007/0005083 A1, US 2007/005083 A1, US 20070005083 A1, US 20070005083A1, US 2007005083 A1, US 2007005083A1, US-A1-20070005083, US-A1-2007005083, US2007/0005083A1, US2007/005083A1, US20070005083 A1, US20070005083A1, US2007005083 A1, US2007005083A1|
|Inventeurs||Sabaratham Sabanathan, Thirumani Sabanathan|
|Cessionnaire d'origine||Sabaratham Sabanathan, Thirumani Sabanathan|
|Exporter la citation||BiBTeX, EndNote, RefMan|
|Référencé par (21), Classifications (18), Événements juridiques (2)|
|Liens externes: USPTO, Cession USPTO, Espacenet|
This application is a continuation of co-pending U.S. patent application Ser. No. 09/762,692, entitled “Occlusion Device”, filed Oct. 31, 2005, which is the National Stage of International PCT Application No. PCT/GB98/00652, entitled “Occlusion Device”, filed Mar. 3, 1998, which claims the benefit of priority to U.K. Patent Application No. 9708681.3, entitled “Lung Treatment Device”, filed Apr. 30, 1997. Disclosures of the aforementioned patent applications are hereby incorporated by reference in their entirety.
The present invention relates to a device useful in the treatment of emphysema and other diseases or disorders of the human or animal lung.
Emphysema is a disease of the lung caused primarily by prolonged smoking, although not exclusively thereby. It is an unrelentless, intractable and debilitating process. Emphysema is defined as an abnormal permanent enlargement of the air spaces distal to the terminal bronchioles, accompanied by destruction of their walls without obvious fibrosis. In this context, destruction means non-uniformity in the pattern of respiratory,airspace enlargement; orderly appearance of the acinus is disturbed and may be lost.
Emphysema causes a physiological loss of lung elastic recoil, which decreases expiratory airflow by loss of driving pressure and premature airway closure from reduced airway traction. The effect of this is that the alveoli become hyper-inflated without there being any real exchange of air with the outside. Therefore the patient begins to feel starved of oxygen and so attempts to breathe more deeply. In breathing more deeply, the effects are exacerbated.
Not only are those individual alveoli which have a block in their respective bronchial tubules affected, but also neighbouring alveoli, perhaps in other regions of the lung, which may otherwise be perfectly serviceable, become affected because the hyper-inflated alveoli pressurise neighbouring alveoli and prevent them from expanding fully. There is, of course, a relatively fixed “exchange” volume of an individual's lung, that is to say, the difference between the expanded volume and the deflated volume. Emphysema reduces the exchange volume because undeflated alveoli occupy that space. Consequently, the only recourse available to the patient is to increase the expanded volume, thereby resulting in the barrel chest symptomatic of emphysema sufferers.
The major therapeutic modalities currently available consist of bronchodilator and anti-inflammatory drugs, directed at decreasing airway resistance, and antibiotics to treat acute and chronic infection. Supplemental oxygen therapy for the hypoxaemic patient improves exercise performance and improves survival in patients with cor pulmonale. Despite all available medical therapies, the course of the disease is one of progressive limitation, increasing dyspnoea and significant increase in overall mortality.
It has long been realised that full lung volume is more than enough for survival in most circumstances and that a person can survive quite satisfactorily with only one lung, for example. Heterogenous distribution of emphysema, together with the lack of pulmonary blood flow to those areas have made lung volume reduction surgery a logical option. Removal of parts of the lung affected by emphysema permits unaffected areas to become operative again and so enable a better quality of life for the patient. Clearly, however, such invasive procedures are of a very serious nature and some patients will not, in any event, be in a sufficiently strong condition to accept the trauma of such procedures. Primarily, the basic relief for emphysema sufferers is inactivity, on the one hand, and breathing pure oxygen, on the other.
Emphysema is a distressing condition affecting a relatively large proportion of the population, and a more effective and less traumatic treatment is required.
On a different matter, other lung conditions sometimes lead to bleeding into the lung. A patient having this condition feels movement of the blood caused by airflow in the lung during breathing, and perceives the blood as a foreign body and irritant. The patient coughs in an attempt to dislodge the perceived foreign body. Coughing blood, of course, is sometimes the first warning of a more serious disease or condition, but once that is realised, there is no benefit in such bleeding. Moreover, in such conditions where the lung might heal itself and subsequently stop bleeding, or indeed simply where the bleeding needs to be confined, the coughing reaction, which is almost impossible to resist, does not help the situation at all, and merely spreads the blood to other areas of the lung.
U.S. Pat. No. 5,382,261 discloses a vessel occluder for providing permanent occlusion of a vessel in a person by use of a flexible closure member attached to at least one radially expandable stent. The occluder does not have barbs or anchors or a stent.
DE-U-9205797 discloses a self expanding ‘meshbasket’ for the occlusion of human hollow organs. The invention is directed to female contraceptive devices and addresses the problem of remaining in place. The device may also find application in embolism therapy and vascular occlusion.
WO-A-9532018 discloses a body passageway closure for use in the occlusion of various passageways within the body, with particular application for the occlusion of blood vessels.
Therefore it is an object of the present invention to provide a method of treatment of certain lung conditions or diseases and to provide a device for such treatment.
In accordance with a first aspect of the present invention there is provided a method of treatment of emphysema or other lung conditions or diseases, the method comprising placing an obturator in a bronchial tube or tubule so as to seal the tube or tubule against the passage of fluid past the obturator.
In the case of emphysema, and by the simple expedient of inserting an obturator in a bronchial tube, a section of a lung can be isolated so that no air can be drawn into it. Thereafter, the isolated part deflates in time as the air remaining in it becomes absorbed, and so that part of the lung stops affecting other areas of the lungs, which can thus perform normally. Such a procedure is relatively simple, requiring only a delivery device for the obturator, which device is inserted through the mouth and airway of the patient until the proposed placement site is reached, whereupon the device is activated to release the obturator from the device.
In the case of bleeding into the lung, an obturator stops the flow of blood. The lung is tamponated by the obturator and blood merely collects in the isolated part of the lung and ultimately, if the bleeding stops, will be reabsorbed. Alternatively, in the case of some, perhaps terminal, conditions such as some lung cancers, it at least provides temporary relief for the patient.
In accordance with a second aspect of the invention there is provided the use of a blocking element and a securing element in the manufacture of an obturator for use in the treatment of a lung condition in a human or animal by blocking a bronchial tube or tubule. The condition may be emphysema.
Preferably the two elements are separate components, the blocking element serving to seal the tube or tubule against the passage of fluid past the obturator when the obturator is disposed in a bronchial tube or tubule, and the securing element serving to retain the blocking element in position in the tube or tubule.
The blocking element preferably comprises a substantially cylindrical plug of biocompatible material. The plug may comprise resiliently deformable closed-cell foamed plastics material, such as PVC, so that it may be compressed to facilitate insertion into the tube or tubule and thereafter expand to fill the cross-section of the tube or tubule.
It is known to employ stents in medical fields to expand and support collapsed blood vessels, and indeed bronchial tubes. A stent is a compressible framework which, when inserted into a vessel and released, expands and, within the limits of its expansion, supports and possibly expands the walls of the vessel.
Preferably, the securing element comprises a stent. The stent may have barbs to engage and retain the blocking element. The stent preferably also has anchors to retain the stent in a bronchial tube or tubule.
In one embodiment, the stent comprises a crown of surgical quality steel wire legs in zig-zag formation. Said barbs and anchors may depend from points of the crown. Preferably the crown is closed in its circumference, although this is not essential.
In another embodiment, the stent comprises a dome of surgical quality steel wire legs. Said barbs and anchors may be formed on the ends of said legs.
It is known in medical fields to block blood vessels, for example where a genetic or other defect has resulted in a hole which needs blocking, or, for example, in the case of babies whose aortic to pulmonary artery connection has not closed following birth, a condition known as patent ductus arteriosus. In the case of holes, it is well known to employ an “umbrella”, where a diaphragm of material forms the seal against the blood vessel wall, the handle of the umbrella serving to keep the diaphragm across the vessel. In the case of babies, it has also been known to employ a plug of PVC foam to treat patent ductus arteriosus, the plug encouraging clotting.
However, in the case of bronchial tubes and tubules a diaphragm seal has not been used yet, although its application cannot be entirely ruled out. For example, an umbrella device with a larger surface area of contact with the bronchial mucosa might be as effective.
In blood vessels a complete seal is seldom required because any leak soon blocks by the formation of a clot; something that would not happen in an airway of a lung. Secondly, airways are not always absolutely circular in section, so a circular diaphragm may not always make a good seal, at least around some parts of the circumference, unless it has capacity to expand in all radial directions and has a large contact area.
However, a complete seal is an absolute requirement of the present invention (at least over the period of a single breath), because without it, air can leak past during inhalation and pressurise the lung in just the same way, and perhaps even to a greater extent. More importantly, however, a patient with such an obturator in place can only feel its presence if there is movement of air around it to stimulate adjacent nerve endings. Once a patient can feel the obturator, there will be irresistible compulsion to cough which, if done excessively, may be sufficient to dislodge the obturator.
Thus it has been found that a very effective seal is achieved by the use of said cylindrical plug of foamed PVC (of the type commonly employed as earplugs). The effectiveness of this arrangement is probably due to the fact that any leakage path has to be a long one and there are thus numerous opportunities for it to close and seal about at least one closed circuit around the plug. Another reason is that a plug can mould itself to the shape of the tube or tubule, which is itself unlikely to be cylindrical, or, indeed, circular in cross-section.
Preferably, the method of the present invention employs an obturator of the type defined above.
The delivery device preferably comprises a delivery tube in which the obturator is received in a compressed state at a distal end thereof, a guide tube, which is capable of following a possibly tortuous path under the guidance of a surgeon from entry into the mouth of a patient, down the patient's trachea and one bronchus to a proposed delivery site in a bronchial tube or tubule, and which has a passage to receive the delivery tube therealong, and release means to eject the obturator from the delivery tube and guide tube.
The obturator needs to slide in the delivery tube during ejection and the stent provides a low friction surface of the obturator to facilitate such ejection.
It is feasible that the blocking and securing elements may be integrally formed from plastics material, and wherein the securing element comprises adhered or fused anchor elements on the blocking element.
It is also feasible that the securing element may comprise a memory metal which is released to its normal expanded shape by a physical parameter, for example, the passage of an electric current therethrough, once it has been inserted at the proposed location. Otherwise it is in the same form as the above described steel stent which relies on resilience for its expansion. The advantage of a memory metal device is that it requires no compression during insertion so that the delivery tube of the delivery device may be replaced by a simple guide rod to which it is connected.
The invention will be better understood from the following description of particular embodiments given as non-limiting examples. The description refers to the accompanying drawings, in which:
In the majority of patients suffering from emphysema, it frequently effects mainly the upper lobes 14 of the lungs, leaving the lower lobes 16 unaffected, or at least less affected. However, if no treatment is given to a patient, the expansion effect of the upper lobes as the condition develops presses on the lower lobes and reduces their capacity to perform efficiently. Lower lobe emphysema does occur in some patients, and in which event it is then the upper lobes which are compressed.
Thus the present invention suggests placing an obturator 50 in a bronchial tube or tubule to isolate the region of the lung supplied by that tube or tubule. Where the obturator is placed will be decided by the surgeon and will depend on the how localised the damaged region of lung is. That is to say, if the whole lobe is badly affected, then the obturator is placed in the lobar bronchus 22 supplying that lobe (as shown at 50 in
The above considerations equally apply when the condition being treated is not emphysema but some other condition which a doctor considers can usefully be treated by the method of the present invention. Such another condition is where a lung, or part of it is bleeding into the airway and an obturator isolates the bleeding region and inhibits coughing which may damage the lung further, or at least cause further discomfort to the patient.
As can be seen from
The stent 90 is constructed from a plurality of legs 91 of surgical grade stainless steel wire welded together such that when extended the stent appears as a series 90 b of connected ‘W’s, as shown in an unconnected disposition in
When the two ends of the stent are joined together, the stent 90 folds into a circular frame or crown, capable of encompassing the biocompatible block 92. The stent is constructed so as to be of a size slightly smaller (in its unstressed condition) than the block, so that its natural resilience squeezes the block slightly. On the other hand, the stent should be larger than the airway into which it is to be introduced so that it presses outwardly against the wall of the airway, and is incorporated into the mucosa of the air passage.
The legs 91 of the stent crown are fitted with both internal barbs 98 and external anchors 100. The barbs 98 embed themselves in the block 92 and secure the block to the stent 90. The anchors 100 are adapted to engage the walls of the patient's airways to hold the stent in position.
The barbs and anchors are joined to the stent crown by a welded joint between two adjacent legs 91. Barbs can alternate with anchors at the same end of the stent, or one end can have all barbs, while the other end has all anchors. Both arrangements are shown in
A different embodiment of obturator 50 b, also in accordance with the present invention, is shown in
The aforementioned obturators all rely on resilience of the steel to return the stent to its original shape once released from the delivery mechanism and so as to enable fitment in a narrower tubule than the unstressed size of the stent would otherwise allow. However, this requires prestressing the stent and keeping it stressed during delivery. Thus the present invention may find suitable application for memory metals, which only return to their original shape when some physical condition changes, for example, temperature rise or electrical current flow.
It is essential for the blocking device 92 to be comprised of a resiliently deformable material such as PVC foam as mentioned above. This enables the blocking device to be easily surrounded by the stent 90 and deformed into a compact structure, thereby enabling delivery of the block to its destination in the lung.
It is likewise essential that the block be capable of expanding and reforming into its original shape once deposited in the desired location in the lungs. It should be noted that the block is deformed and reformed in both an axial and a radial direction. It is the block 92 which seals a bronchial tube or tubule; mucous surrounds the block and forms a fluid tight seal. The presence of the stent around the block does not inhibit sealing in any way since the stent is essentially incorporated into the mucosa lining the airway.
Under compression, PVC foam has a high coefficient of friction which would prevent ejection from the delivery device as described above, if it was not surrounded by the stent 90, which offers a relatively low friction surface to the inside of delivery tube 76.
However, it is feasible that the block 92 could include a low friction surface to enable such ejection without the stent. Instead of the stent as described above, anchor means might be moulded in biocompatible plastics material as a crown, for example, on one end of the block, and either be adhered, fused or otherwise bound thereto.
The effectiveness of the device depends, to some extent, on the length of the block. Moreover, the block is required to be of a size which is both comfortable to the patient once expanded in the lung and which expands to completely obstruct the passage of air into the affected portions of the lung. The extended size of the block therefore ranges between 5 mm and 25 mm in length, and between 5 and 11 mm in diameter, depending on the size of the tube or tubule to be obturated.
Obturator 50 c shown in
Finally, as mentioned above, the obturator may be as shown at 50 d in
While the obturator and method of the present invention has been described with reference to human patients, animal patients may in certain circumstances also benefit.
|Brevet citant||Date de dépôt||Date de publication||Déposant||Titre|
|US7682332||30 juin 2004||23 mars 2010||Portaero, Inc.||Methods to accelerate wound healing in thoracic anastomosis applications|
|US7686013||12 févr. 2008||30 mars 2010||Portaero, Inc.||Variable resistance pulmonary ventilation bypass valve|
|US7726305||12 févr. 2008||1 juin 2010||Portaero, Inc.||Variable resistance pulmonary ventilation bypass valve|
|US7753052||6 févr. 2008||13 juil. 2010||Portaero, Inc.||Intra-thoracic collateral ventilation bypass system|
|US7789083||31 janv. 2008||7 sept. 2010||Portaero, Inc.||Intra/extra thoracic system for ameliorating a symptom of chronic obstructive pulmonary disease|
|US7811274||27 avr. 2004||12 oct. 2010||Portaero, Inc.||Method for treating chronic obstructive pulmonary disease|
|US7824366||10 déc. 2004||2 nov. 2010||Portaero, Inc.||Collateral ventilation device with chest tube/evacuation features and method|
|US7828789||7 avr. 2008||9 nov. 2010||Portaero, Inc.||Device and method for creating a localized pleurodesis and treating a lung through the localized pleurodesis|
|US7896008||6 août 2007||1 mars 2011||Portaero, Inc.||Lung reduction system|
|US7909803||18 févr. 2009||22 mars 2011||Portaero, Inc.||Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease|
|US7927324||18 févr. 2009||19 avr. 2011||Portaero, Inc.||Aspirator and method for pneumostoma management|
|US7931641||21 févr. 2008||26 avr. 2011||Portaero, Inc.||Visceral pleura ring connector|
|US8136526||7 mars 2007||20 mars 2012||Pulmonx Corporation||Methods and devices to induce controlled atelectasis and hypoxic pulmonary vasoconstriction|
|US8342182||27 août 2007||1 janv. 2013||Pulmonx Corporation||Functional assessment and treatment catheters and methods for their use in the lung|
|US8632605||11 sept. 2009||21 janv. 2014||Pneumrx, Inc.||Elongated lung volume reduction devices, methods, and systems|
|US8986338||29 oct. 2009||24 mars 2015||Cook Biotech Incorporated||Vascular plugs|
|US9050094||19 mars 2009||9 juin 2015||Pulmonx Corporation||Methods and devices for passive residual lung volume reduction and functional lung volume expansion|
|US20040225254 *||27 avr. 2004||11 nov. 2004||Don Tanaka||Localized pleurodesis chemical delivery|
|US20040237966 *||20 mai 2004||2 déc. 2004||Don Tanaka||Methods and devices to assist pulmonary decompression|
|US20040244803 *||24 mai 2004||9 déc. 2004||Don Tanaka||Intra-thoracic collateral ventilation bypass system|
|US20050025816 *||30 juin 2004||3 févr. 2005||Don Tanaka||Methods and devices to accelerate wound healing in thoracic anastomosis applications|
|Classification aux États-Unis||606/157, 623/23.7|
|Classification internationale||A61B17/24, A61F2/86, A61B17/12|
|Classification coopérative||A61B17/12177, A61B17/12104, A61B17/12022, A61B2017/1205, A61B17/12172, A61B17/12159, A61B17/12136|
|Classification européenne||A61B17/12P7W1, A61B17/12P7B, A61B17/12P7W3, A61B17/12P7P, A61B17/12P5A, A61B17/12P|
|8 févr. 2007||AS||Assignment|
Owner name: EMPHASYS MEDICAL, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SABANATHAN, THIRUMANI;BRADFORD HOSPITALS NHS TRUST;FOUNDRY, LLC, THE;REEL/FRAME:018880/0210
Effective date: 20010720
Owner name: EMPHASYS MEDICAL, INC., CALIFORNIA
Free format text: SUPPLEMENT TO AGREEMENT OF JUNE 6, 2000.;ASSIGNOR:THIRUMANI SABANATHAN, BRADFORD HOSPITALS NHS TRUST AND THE FOUNDRY, LLC;REEL/FRAME:018880/0172
Effective date: 20010119
Owner name: FOUNDRY, LLC, THE, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SABANATHAN, THIRUMANI;BRADFORD HOSPITALS NHS TRUST;REEL/FRAME:018880/0051
Effective date: 20000606
|21 juin 2009||AS||Assignment|
Owner name: PULMONX, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EMPHASYS MEDICAL, INC.;REEL/FRAME:022852/0851
Effective date: 20090331